Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,182 across all filing types
Latest filing 2021-06-11 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Lupin donates Oxygen generation plants in Maharashtra, Madhya Pradesh & Gujarat to aid COVID-19 relief efforts.
Regulatory Filings Classification · 95% confidence The document is a press release dated June 11, 2021, disclosing a donation of oxygen generation plants by Lupin Limited through its CSR arm to assist states in India during the COVID-19 pandemic. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The content is a corporate announcement about a CSR activity and does not contain financial statements, management discussion, or detailed financial data. The document length is 4069 characters, which is relatively short and consistent with a press release or regulatory announcement. It is not an annual or interim report, earnings release, or any other detailed financial or governance report. It is a regulatory announcement about a corporate social responsibility initiative. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-06-11 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Lupin Limited has received U.S. FDA approval for a pharmaceutical product. It is addressed to stock exchanges as a disclosure pursuant to SEBI regulations. The content is a corporate announcement about a regulatory approval event, not a financial report, earnings release, or management discussion. The document length is 4385 characters, which is relatively short and typical for a press release. There is no financial data, no discussion of financial results, no voting results, no management changes, no legal proceedings, and no detailed investor presentation. The document is clearly a regulatory announcement about a significant corporate event (FDA approval) and is filed under SEBI Regulation 30 disclosure requirements. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-06-07 English
Lupin Receives U.S. FDA Approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets.
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Lupin Limited has received U.S. FDA approval for a pharmaceutical product. It is addressed to stock exchanges as a disclosure pursuant to SEBI regulations. The content is a corporate announcement about regulatory approval and product marketing, not a financial report, earnings release, or management discussion. The document length is 4386 characters, which is relatively short and typical for a press release. There is no financial data, no discussion of financial results, no voting results, no board changes, no legal proceedings, and no detailed investor presentation. Therefore, this document fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and disclosures that do not fit other specific categories.
2021-06-07 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of Lupin Limited's Digital Asthma Educator platform. It is addressed to stock exchanges as a disclosure pursuant to SEBI regulations, indicating it is a regulatory announcement. The content focuses on the product launch and company initiative rather than financial results, management changes, or detailed financial data. The document length is about 5850 characters, which is relatively short and typical for a press release. There is no indication of financial statements, earnings data, or detailed report content. Therefore, this document fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement and disclosure rather than a financial report or other specific filing type.
2021-06-07 English
Lupin Launches Digital Asthma Educator platform.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new Digital Asthma Educator platform by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to SEBI regulations, indicating it is a regulatory announcement. The content focuses on the product launch and company information, without any financial data, financial results, or detailed report content. The document length is about 5858 characters, which is relatively short and typical for a press release. There is no indication that this is an annual report, earnings release, management discussion, or any other detailed financial or governance report. It is not a report publication announcement since it does not mention any report being attached or published. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and disclosures that do not fit other specific categories.
2021-06-07 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of an authorized generic version of a pharmaceutical product by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to SEBI regulations. The content is a corporate announcement about a product launch, not a financial report, regulatory filing, or management information. The document length is short (3898 characters) and contains no financial data or detailed report content. Therefore, it fits best under the category of a Regulatory Filing (RNS) as a general regulatory announcement and disclosure under listing obligations.
2021-06-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.